This is a transformative reverse merger that effectively replaces Passage Bio with Remix Therapeutics. Traders should view this as a new entity with a different pipeline and management. The key catalyst is the successful closing of the merger and the concurrent PIPE, which provides the combined company with a substantial cash runway. Monitor the stockholder votes and regulatory approvals for the merger.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 3 $4.75entry
- T+1 · 2mo ago −2.11%α −1.72% · $4.65
- T+5 · 2mo ago +5.26%α +6.41% · $5.00
- T+20 · 7w ago −13.26%α −12.08% · $4.12
- T+51 · todayOpen
- T+60 · in 13d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Passage Bio (PASG) is acquiring Remix Therapeutics in a reverse-merger transaction valued at $226M for Remix's equity, with a concurrent $99.9M PIPE financing. The combined company will operate under the Remix name and pipeline, with Passage's existing assets (Legacy Assets) being divested and their proceeds distributed to Passage's pre-merger shareholders via Contingent Value Rights (CVRs). This is a transformative event that effectively replaces Passage's business with Remix's, making it a new entity for investors.
Key Financial Metrics
Key Facts
- Passage Bio is acquiring Remix Therapeutics via a two-step merger, with Remix valued at $226M in equity.
- A concurrent PIPE financing of at least $99.9M is being raised to fund the combined company.
- Passage's existing assets (Legacy Assets) will be sold, with proceeds distributed to pre-merger Passage shareholders through CVRs.
- The combined company will be named Remix Therapeutics, Inc., and Passage's current management will be replaced by Remix's team.
- The transaction requires approval from both Passage and Remix stockholders, with a target closing by December 24, 2026.
Financial Impact
Remix equity valued at $226M; concurrent PIPE of at least $99.9M; Passage equity valued at $20M.
Risk Factors
- The merger may fail to close if stockholder votes or regulatory approvals are not obtained.
- The Legacy Asset Disposition may not be completed, or the CVRs may pay out zero.
- The combined company's pipeline (Remix's) is still pre-commercial and carries clinical and regulatory risk.
- The concurrent PIPE may not close, leaving the combined company undercapitalized.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035515 |
| Document: ef20081513_ex10-6.htm | 0001140361-26-035515 |
| Document: ef20081513_ex10-4.htm | 0001140361-26-035515 |
Track record
15 reports on PASG
2 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
- Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
- Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
- Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
- Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
- Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
- Sep 2, 202610w ago 8-K Bullish 8/10 Viewing Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
- Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers